Videos

John Mascarenhas, MD, and Ruben Mesa, MD, share insights on the evolving treatment landscape of myelofibrosis.

Neal Shore, MD, FACS, discusses the use of metastases-free survival as the primary end point in the ARAMIS trial, which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).

Neal Shore, MD, FACS, explains the relationship between the use of darolutamide and control of urinary and bowel adverse events, as observed in an analysis of the phase 3 ARAMIS clinical trial.

Ramez Eskander, MD, summarizes the current status of ovarian cancer treatment and reviews unanswered questions and future directions.

Dr Ramez Eskander shares his insights on considerations for selecting appropriate PARP inhibitor therapy for patients based on molecular testing and other factors.

An expert in ovarian cancer discusses the mechanism of action of PARP inhibitors in treating advanced ovarian cancer and comments on tolerability profiles of available agents.

Ramez Eskander, MD, describes the ARIEL3 study of rucaparib switch maintenance therapy in patients with advanced ovarian cancer.

Dr Ramez Eskander reviews the options and goals for frontline maintenance therapy in women with advanced ovarian cancer.

An expert in ovarian cancer reviews best practices for molecular testing in patients with advanced ovarian cancer and the implications of testing results for treatment selections.

Ramez Eskander, MD, discusses the case of a 64-year-old woman diagnosed with ovarian cancer.

Alicia K. Morgans, MD, PhD, discusses the cardiovascular risks associated with androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer.

Sarat Chandarlapaty, MD, offers his opinion on the potential roles amcenestrant could have in the treatment of ER+/HER2- metastatic breast cancer.

Dr Chandarlapaty discusses the AMEERA-1 trial and its impact on the ER+/HER2- metastatic breast cancer landscape.

An expert introduces amcenestrant as a potential new therapy for ER+/HER2- metastatic breast cancer and addresses how it differs from current treatment options.

Dr Chandarlapaty elaborates on the challenges and unmet needs seen when treating ER+/HER2- metastatic breast cancer.

A medical oncologist discusses the available treatment options for ER+/HER2- metastatic breast cancer.

Recommendations for preventing and mitigation infection risk in patients with chemotherapy-induced neutropenia in the adjuvant setting.

Sarat Chandarlapaty, MD, gives an overview of ER+/HER2- metastatic breast cancer, including characteristics, diagnosis, and prognosis.

Implications of severity and sequelae of chemotherapy-induced neutropenia for disease management.

Nelson J. Chao, MD, discusses a shift at Duke Cancer Institute from in-office care to home care in patients undergoing hematopoietic stem cell transplantation for hematologic malignancies.

Smruthy Sivakumar, PhD, discusses a large-scale analysis of comprehensive genomic profiling utilization and ancestral characterization of the genomic landscape in patients with advanced prostate cancer.

Elisa Agostinetto, MD, of the Istituto Clinico Humanitas in Rozzano, Milan, Italy, discussed the rational of investigating the accuracy of PREDICT+ in HER2-positive breast cancer.

Drs Neeraj Agarwal and Petros Grivas comment on biomarkers and novel therapies under investigation for advanced urothelial carcinoma and remark on the next steps for treating patients with antibody-drug conjugates.

Expert hematologist-oncologists comment on the optimization of JAK inhibitor therapies, including ruxolitinib, momelotinib, fedratinib, and pacritinib, in myelofibrosis treatment.

Strategies to help manage treatment-related toxicities to novel therapies used in the management of advanced urothelial carcinoma.

Drs Ruben Mesa and John Mascarenhas review therapies and drugs in development for the treatment of myelofibrosis as seen in the COMFORT, JAKARTA, MOMENTUM, PACIFICA, and PERSIST trials.

The importance of collecting patient-reported outcomes data in urothelial carcinoma as it relates to novel treatment selection.

Amaia Lujambio Goizueta, PhD, discusses mutations commonly seen in hepatocellular carcinoma, and the targeted therapies available for these tumors.

Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, provide an overview of their major conclusions and clinical pearls for the treatment approach of EGFR Exon 20 Insertion+ NSCLC.

Experts review the toxicity of mobocertinib and further discuss the key findings from the EXCLAIM Trial.